Eton Pharmaceuticals, Inc. Common Stock (ETON) Stock
Key stats
- Market cap
- $1.97B
- Price / Earnings ratio
- 39.1x
- EPS (TTM)
- $1.77
- Volume
- Loading
- 52-week high
- $68.38
- 52-week low
- $14.27
Source: third-party data provider, as of November 13, 2026
Compare with ETON
Recent news

ETON Gears Up to Report Q3 Earnings: What Can Investors Expect?
ETON Gears Up to Report Q3 Earnings: What Can Investors Expect?
ETON

Why Eton Pharmaceuticals Is Top of the Class Today
Why Eton Pharmaceuticals Is Top of the Class Today
ETON

This Analyst Believes Eton Pharma’s Raised Guidance Is ‘Conservative’ – ETON Stock Heads For Best Ever Day
This Analyst Believes Eton Pharma’s Raised Guidance Is ‘Conservative’ – ETON Stock Heads For Best Ever Day
ETON

Why Top 3% Biotech Stock, Eton, Just Catapulted To A Record High
Why Top 3% Biotech Stock, Eton, Just Catapulted To A Record High
ETON
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 73.32
- MACD 12/26/9
- 2.38
- EMA 9 of MACD
- 0.23
- MACD histogram
- 2.15
- SMA 50
- $55.19
- Price above SMA 50
- EMA 50
- $53.97
- Price above EMA 50
- SMA 200
- $37.38
- Price above SMA 200
- EMA 200
- $38.48
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

ETON Gears Up to Report Q3 Earnings: What Can Investors Expect?
ETON Gears Up to Report Q3 Earnings: What Can Investors Expect?
ETON

Why Eton Pharmaceuticals Is Top of the Class Today
Why Eton Pharmaceuticals Is Top of the Class Today
ETON

This Analyst Believes Eton Pharma’s Raised Guidance Is ‘Conservative’ – ETON Stock Heads For Best Ever Day
This Analyst Believes Eton Pharma’s Raised Guidance Is ‘Conservative’ – ETON Stock Heads For Best Ever Day
ETON

Why Top 3% Biotech Stock, Eton, Just Catapulted To A Record High
Why Top 3% Biotech Stock, Eton, Just Catapulted To A Record High
ETON

Eton Pharmaceuticals Q2 Earnings Call Highlights
Eton Pharmaceuticals Q2 Earnings Call Highlights
ETON

Eton Pharmaceuticals, Inc. (ETON) Q2 Earnings and Revenues Beat Estimates
Eton Pharmaceuticals, Inc. (ETON) Q2 Earnings and Revenues Beat Estimates
ETON

ETON Stock Jumps 10%: Why Does This Analyst See 47% Upside To Stock?
ETON Stock Jumps 10%: Why Does This Analyst See 47% Upside To Stock?
ETON

Eton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last?
Eton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last?
ETON

Eton Pharmaceuticals Q1 Earnings Call Highlights
Eton Pharmaceuticals Q1 Earnings Call Highlights
ETON

Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates
Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates
ETON
News tone: automated (AI) classification of the article's content, not a price prediction.
About Eton Pharmaceuticals, Inc. Common Stock
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Sean E. Brynjelsen | President, CEO & Director | 1972 |
| Ms. Judith M. Matthews | Chief Financial Officer & Secretary | 1970 |
| Ms. Danka Radosavljevic | Chief Operating Officer | 1984 |
| Mr. David C. Krempa | Chief Business Officer | 1989 |
| Mr. James R. Gruber CPA | Consultant | 1972 |
| Ms. Ipek Erdogan-Trinkaus | Chief Commercial Officer | 1982 |
| Mr. Scott Grossenbach | Senior Vice President of Sales Operations | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 73.32
- MACD 12/26/9
- 2.38
- EMA 9 of MACD
- 0.23
- MACD histogram
- 2.15
- SMA 50
- $55.19
- Price above SMA 50
- EMA 50
- $53.97
- Price above EMA 50
- SMA 200
- $37.38
- Price above SMA 200
- EMA 200
- $38.48
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $80.00
- Average
- $80.33
- High
- $81.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.6 | +5.4 | +26.2 | +26.7 | +33.9 | -14.8 | +0.4 | +34.6 |



